Bristol Myers Squibb Co

USPTO Trademark & Patent Filings

Bristol Myers Squibb Co
Trademark Applications
Mark Image

Registration | Serial
Trademark
Application Date
CLICKJECT
"CLICKJECT"
85229745
CLICKJECT
2011-01-31
BRISTOL-MYER SQUIBB FOUNDATION MENTAL HEALTH & WELL-BEING ADVANCING UNDERSTANDING, CARE AND SUPPORT
"BRISTOL-MYER SQUIBB FOUNDATION MENTAL HEALTH & WELL-BEING ADVANCING UNDERSTANDING, CARE AND SUPPORT"
85228456
BRISTOL-MYER SQUIBB FOUNDATION MENTAL HEALTH & WELL-BEING ADVANCING UNDERSTANDING, CARE AND SUPPORT
2011-01-28
ADVOCATE
"ADVOCATE"
85228829
ADVOCATE
2011-01-28
NUVALOJIX
"NUVALOJIX"
85227644
NUVALOJIX
2011-01-27
ORENCIA DIRECTJECT
"ORENCIA DIRECTJECT"
85227651
ORENCIA DIRECTJECT
2011-01-27
I CAN WITH RA IN THE KITCHEN
"I CAN WITH RA IN THE KITCHEN"
85225547
I CAN WITH RA IN THE KITCHEN
2011-01-25
AFORE - ABATACEPT VERSUS ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN BIOLOGIC-NAIVE SUBJECTS WITH BACKGROUND METHOTREXATE
"AFORE - ABATACEPT VERSUS ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN BIOLOGIC-NAIVE SUBJECTS WITH BACKGROUND METHOTREXATE"
85222810
AFORE - ABATACEPT VERSUS ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN BIOLOGIC-NAIVE SUBJECTS WITH BACKGROUND METHOTREXATE
2011-01-21
FULLCLICK
"FULLCLICK"
85220624
FULLCLICK
2011-01-19
VALIDOSE
"VALIDOSE"
85220653
VALIDOSE
2011-01-19
QUETOUCH
"QUETOUCH"
85220641
QUETOUCH
2011-01-19
COMFICLICK
"COMFICLICK"
85220628
COMFICLICK
2011-01-19
QUTOUCH
"QUTOUCH"
85220642
QUTOUCH
2011-01-19
COMFICLIQ
"COMFICLIQ"
85220631
COMFICLIQ
2011-01-19
SQ-COMFORT
"SQ-COMFORT"
85220645
SQ-COMFORT
2011-01-19
GENCLICK
"GENCLICK"
85220634
GENCLICK
2011-01-19
SQ-TOUCH
"SQ-TOUCH"
85220646
SQ-TOUCH
2011-01-19
JUSTCLICK
"JUSTCLICK"
85220636
JUSTCLICK
2011-01-19
ACTIVJEX
"ACTIVJEX"
85220623
ACTIVJEX
2011-01-19
SUREQ
"SUREQ"
85220649
SUREQ
2011-01-19
Q-TOUCH
"Q-TOUCH"
85220638
Q-TOUCH
2011-01-19
BMS VIRTUAL LIBRARY
"BMS VIRTUAL LIBRARY"
85216540
BMS VIRTUAL LIBRARY
2011-01-13
EBYAV
"EBYAV"
85199555
EBYAV
2010-12-16
EBYZON
"EBYZON"
85199560
EBYZON
2010-12-16
KEBYONT
"KEBYONT"
85199567
KEBYONT
2010-12-16
XOGLYXO
"XOGLYXO"
85195086
XOGLYXO
2010-12-10
DAPAGLEZE
"DAPAGLEZE"
85195088
DAPAGLEZE
2010-12-10
DAPLICISE
"DAPLICISE"
85195093
DAPLICISE
2010-12-10
MAZYTI
"MAZYTI"
85189355
MAZYTI
2010-12-02
EBYSTRYDE
"EBYSTRYDE"
85189365
EBYSTRYDE
2010-12-02
NEXTUBIN
"NEXTUBIN"
85189021
NEXTUBIN
2010-12-02
JEZRET
"JEZRET"
85189322
JEZRET
2010-12-02
I WANT, I CAN
"I WANT, I CAN"
85181117
I WANT, I CAN
2010-11-19
EBYMEC
"EBYMEC"
85181147
EBYMEC
2010-11-19
THE BE-LOW STUDY
"THE BE-LOW STUDY"
85176864
THE BE-LOW STUDY
2010-11-15
VIK VERY IMPORTANT KIDS
"VIK VERY IMPORTANT KIDS"
85172468
VIK VERY IMPORTANT KIDS
2010-11-09
AUTISM LET'S TALK ABOUT IT CLINICAL RESEARCH TRIAL
"AUTISM LET'S TALK ABOUT IT CLINICAL RESEARCH TRIAL"
85172453
AUTISM LET'S TALK ABOUT IT CLINICAL RESEARCH TRIAL
2010-11-09
ACQUIRE- ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE
"ACQUIRE- ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE"
85164740
ACQUIRE- ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE
2010-10-29
ALLOW- EVALUATION OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY IN ADULTS WITH ACTIVE RHEUMATOID ARTHRITIS; IMPACT OF WITHDRAWAL AND
"ALLOW- EVALUATION OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY IN ADULTS WITH ACTIVE RHEUMATOID ARTHRITIS; IMPACT OF WITHDRAWAL AND "
85164758
ALLOW- EVALUATION OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY IN ADULTS WITH ACTIVE RHEUMATOID ARTHRITIS; IMPACT OF WITHDRAWAL AND
2010-10-29
ATTUNE - ABATACEPT IN SUBJECTS WHO SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS THERAPY
"ATTUNE - ABATACEPT IN SUBJECTS WHO SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS THERAPY"
85164770
ATTUNE - ABATACEPT IN SUBJECTS WHO SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS THERAPY
2010-10-29
ACCOMPANY - ABATACEPT IN SUBJECTS WITH RHEUMATOID ARTHRITIS ADMINISTERED PLUS OR MINUS BACKGROUND METHOTREXATE SUBCUTANEOUSLY
"ACCOMPANY - ABATACEPT IN SUBJECTS WITH RHEUMATOID ARTHRITIS ADMINISTERED PLUS OR MINUS BACKGROUND METHOTREXATE SUBCUTANEOUSLY"
85164893
ACCOMPANY - ABATACEPT IN SUBJECTS WITH RHEUMATOID ARTHRITIS ADMINISTERED PLUS OR MINUS BACKGROUND METHOTREXATE SUBCUTANEOUSLY
2010-10-29
THETYPE2TALK.COM CHANGING THE TYPE 2 DIABETES CONVERSATION
"THETYPE2TALK.COM CHANGING THE TYPE 2 DIABETES CONVERSATION"
85156755
THETYPE2TALK.COM CHANGING THE TYPE 2 DIABETES CONVERSATION
2010-10-20
RALIVING
"RALIVING"
4768866 85154633
RALIVING
2010-10-18
REALRALIVING
"REALRALIVING"
85154638
REALRALIVING
2010-10-18
TOGETHER ON DIABETES
"TOGETHER ON DIABETES"
4165272 85155051
TOGETHER ON DIABETES
2010-10-18
KOMBOGLYZE
"KOMBOGLYZE"
85141043
KOMBOGLYZE
2010-09-29
SPRING SUPPORT, PATIENT RESOURCES, INFORMATION AND GUIDANCE
"SPRING SUPPORT, PATIENT RESOURCES, INFORMATION AND GUIDANCE"
85140935
SPRING SUPPORT, PATIENT RESOURCES, INFORMATION AND GUIDANCE
2010-09-29
BE MELANOMA SMART
"BE MELANOMA SMART"
85138726
BE MELANOMA SMART
2010-09-27
NULOJIC
"NULOJIC"
85130864
NULOJIC
2010-09-16
ASSIGN
"ASSIGN"
85129813
ASSIGN
2010-09-15
BYONMET
"BYONMET"
85124057
BYONMET
2010-09-07
ORZINDO
"ORZINDO"
85108879
ORZINDO
2010-08-17
CML TREATMENT COMPANION
"CML TREATMENT COMPANION"
85104733
CML TREATMENT COMPANION
2010-08-11
EBYONT
"EBYONT"
85101701
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101735
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101752
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101669
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101763
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101676
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101679
EBYONT
2010-08-06
EBYONT
"EBYONT"
85101037
EBYONT
2010-08-05
EBYONT
"EBYONT"
85101068
EBYONT
2010-08-05
YERVOY
"YERVOY"
85075624
YERVOY
2010-07-01
WINGLORE
"WINGLORE"
85075628
WINGLORE
2010-07-01
MANAGE TYPE 2 TODAY
"MANAGE TYPE 2 TODAY"
85069295
MANAGE TYPE 2 TODAY
2010-06-23
ELIQUYZ
"ELIQUYZ"
85069396
ELIQUYZ
2010-06-23
DEMONSTRATE: DRUG EVALUATION IN MELANOMA: ONCOLOGY STUDY AND RESEARCH OF IPILIMUMAB
"DEMONSTRATE: DRUG EVALUATION IN MELANOMA: ONCOLOGY STUDY AND RESEARCH OF IPILIMUMAB"
85064237
DEMONSTRATE: DRUG EVALUATION IN MELANOMA: ONCOLOGY STUDY AND RESEARCH OF IPILIMUMAB
2010-06-16
ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT
"ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT"
85063047
ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT
2010-06-15
IDEATE: IPILIMUMAB DRUG EVALUATION
"IDEATE: IPILIMUMAB DRUG EVALUATION"
85062176
IDEATE: IPILIMUMAB DRUG EVALUATION
2010-06-14
"Symbol/Image"
85055847
Symbol/Image
2010-06-07
FACEHEPB.COM
"FACEHEPB.COM"
4064209 85055853
FACEHEPB.COM
2010-06-07
FACEHEPB.COM
"FACEHEPB.COM"
4064210 85055858
FACEHEPB.COM
2010-06-07
FACEHEPB.COM IT'S YOUR LIVER. TAKE CHARGE NOW.
"FACEHEPB.COM IT'S YOUR LIVER. TAKE CHARGE NOW."
4080820 85055860
FACEHEPB.COM IT'S YOUR LIVER. TAKE CHARGE NOW.
2010-06-07
D- LITE - DIRECT ACTING ANTIVIRALS LAMBDA INTERFERON TREATMENT EVALUATION
"D- LITE - DIRECT ACTING ANTIVIRALS LAMBDA INTERFERON TREATMENT EVALUATION"
85049293
D- LITE - DIRECT ACTING ANTIVIRALS LAMBDA INTERFERON TREATMENT EVALUATION
2010-05-27
DUOGYZE
"DUOGYZE"
85045976
DUOGYZE
2010-05-24
DUOGYZA
"DUOGYZA"
85045977
DUOGYZA
2010-05-24
FULGLYZA
"FULGLYZA"
85044655
FULGLYZA
2010-05-21
"Symbol/Image"
85042471
Symbol/Image
2010-05-19
REALM
"REALM"
85041151
REALM
2010-05-18
REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHER
"REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHER"
85041166
REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHER
2010-05-18
THE ORENCIA COPAY PROGRAM
"THE ORENCIA COPAY PROGRAM"
4280165 85038498
THE ORENCIA COPAY PROGRAM
2010-05-14
YOUR VOYAGE
"YOUR VOYAGE"
4234416 85031827
YOUR VOYAGE
2010-05-06
ME MARKETING EXCELLENCE CHARTING A COURSE FOR THE FUTURE
"ME MARKETING EXCELLENCE CHARTING A COURSE FOR THE FUTURE"
85024278
ME MARKETING EXCELLENCE CHARTING A COURSE FOR THE FUTURE
2010-04-27
"Symbol/Image"
85021472
Symbol/Image
2010-04-23
"Symbol/Image"
4198957 85021465
Symbol/Image
2010-04-23
"Symbol/Image"
4198958 85021469
Symbol/Image
2010-04-23
ALEXANDER
"ALEXANDER"
85019512
ALEXANDER
2010-04-21
"Symbol/Image"
85016919
Symbol/Image
2010-04-19
JEMETEM
"JEMETEM"
85012554
JEMETEM
2010-04-13
SHARP STATE HEALTHCARE ACCESS RESEARCH PROJECT
"SHARP STATE HEALTHCARE ACCESS RESEARCH PROJECT"
85003127
SHARP STATE HEALTHCARE ACCESS RESEARCH PROJECT
2010-03-31
MY NULOJIX (BELATACEPT) NETWORK
"MY NULOJIX (BELATACEPT) NETWORK"
4195030 77968613
MY NULOJIX (BELATACEPT) NETWORK
2010-03-25
APPEAR
"APPEAR"
77951725
APPEAR
2010-03-05
BRISTOL-MYERS SQUIBB
"BRISTOL-MYERS SQUIBB"
4047440 77950600
BRISTOL-MYERS SQUIBB
2010-03-04
GREXLO
"GREXLO"
77944902
GREXLO
2010-02-25
ONGLIP
"ONGLIP"
77944882
ONGLIP
2010-02-25
ONGLIPA
"ONGLIPA"
77944885
ONGLIPA
2010-02-25
MY SPRYCEL SUPPORT
"MY SPRYCEL SUPPORT"
4099558 77942400
MY SPRYCEL SUPPORT
2010-02-23
"Symbol/Image"
77942410
Symbol/Image
2010-02-23
SPRYCEL
"SPRYCEL"
3845228 77941220
SPRYCEL
2010-02-22
DURSPONSE
"DURSPONSE"
77941172
DURSPONSE
2010-02-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed